{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:07:37Z","timestamp":1791914857665,"version":"4.3.4"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012465","name":"Zunyi Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.intimp.2025.114360","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:15:37Z","timestamp":1741184137000},"page":"114360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Severe asthma beyond bronchodilators: Emerging therapeutic approaches"],"prefix":"10.1016","volume":"152","author":[{"given":"Muhammad Qasim","family":"Barkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Salawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaddique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2025.114360_bb0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/13543784.2016.1175434","article-title":"Investigational prostaglandin D2 receptor antagonists for airway inflammation","volume":"25","author":"Santini","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.intimp.2025.114360_bb0010","first-page":"1","article-title":"The current state of biologic therapies for treatment of refractory asthma","author":"Mavissakalian","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40733-018-0039-4","article-title":"Single nucleotide polymorphisms in asthma candidate genes TBXA2R, ADAM33 FCER1B and ORMDL3 in Pakistani asthmatics a case control study","volume":"4","author":"Saba","year":"2018","journal-title":"Asthma Res. Practice"},{"issue":"6","key":"10.1016\/j.intimp.2025.114360_bb0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/08923973.2020.1824238","article-title":"New perspectives in bronchial asthma: pathological, immunological alterations, biological targets, and pharmacotherapy","volume":"42","author":"Mandlik","year":"2020","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2025.114360_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114012","article-title":"Promises and challenges of biologics for severe asthma","volume":"179","author":"Tan","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114360_bb0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12016-016-8578-z","article-title":"Immunology, CD26 and asthma: a comprehensive review","volume":"56","author":"Nieto-Fontarigo","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0040","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00826-2023","article-title":"Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies","volume":"64","author":"Liu","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0045","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-024-02812-3","article-title":"Barriers to clinical remission in severe asthma","volume":"25","author":"Farinha","year":"2024","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12931-018-0912-y","article-title":"Efficacy and safety of antagonists for chemoattractant receptor-homologous molecule expressed on Th2 cells in adult patients with asthma: a meta-analysis and systematic review","volume":"19","author":"Yang","year":"2018","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0055","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11136-014-0801-x","article-title":"A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales","volume":"24","author":"Hyland","year":"2015","journal-title":"Qual. Life Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.114360_bb0060","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/thoraxjnl-2013-204114","article-title":"The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society difficult asthma registry","volume":"70","author":"O\u2019Neill","year":"2015","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0065","first-page":"7","article-title":"Key recommendations for primary care from the 2022 global initiative for asthma (GINA) update, npj primary care","volume":"33","author":"Levy","year":"2023","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0070","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1164\/ajrccm.151.5.7735578","article-title":"The assessment and management of adults with status asthmaticus","volume":"151","author":"Corbridge","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0075","first-page":"177","article-title":"Pharmacology of long-acting beta-agonists, annals of allergy, asthma & immunology: official publication of the American College of Allergy","volume":"75","author":"Johnson","year":"1995","journal-title":"Asthma, Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00002018-199716050-00002","article-title":"Airway subsensitivity with long-acting \u03b2 2-agonists","volume":"16","author":"Lipworth","year":"1997","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/cc1451","article-title":"Clinical review: severe asthma","volume":"6","author":"Papiris","year":"2001","journal-title":"Crit. Care"},{"key":"10.1016\/j.intimp.2025.114360_bb0090","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0954-6111(02)90077-6","article-title":"The role of inflammation and anti-inflammatory medication in asthma","volume":"96","author":"Barnes","year":"2002","journal-title":"Respir. Med."},{"issue":"13","key":"10.1016\/j.intimp.2025.114360_bb0095","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","article-title":"Tiotropium in asthma poorly controlled with standard combination therapy","volume":"367","author":"Kerstjens","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0100","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/ph3030725","article-title":"Theophylline","volume":"3","author":"Barnes","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.intimp.2025.114360_bb0105","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3109\/02770903.2013.823447","article-title":"A review on leukotrienes and their receptors with reference to asthma","volume":"50","author":"Singh","year":"2013","journal-title":"J. Asthma"},{"issue":"1\u20133","key":"10.1016\/j.intimp.2025.114360_bb0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2005.12.072","article-title":"Anticholinergic agents in asthma and COPD","volume":"533","author":"Gross","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114360_bb0115","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1378\/chest.121.6.1977","article-title":"The role of anticholinergics in acute asthma treatment: an evidence-based evaluation","volume":"121","author":"Rodrigo","year":"2002","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.intimp.2025.114360_bb0120","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11325-011-0639-1","article-title":"The actual role of sodium cromoglycate in the treatment of asthma\u2014a critical review","volume":"16","author":"Netzer","year":"2012","journal-title":"Sleep Breath."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0125","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00670-2017","article-title":"Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids","volume":"50","author":"Bateman","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1631\/jzus.B2300409","article-title":"Endoplasmic reticulum stress-induced NLRP3 inflammasome activation as a novel mechanism of polystyrene microplastics (PS-MPs)-induced pulmonary inflammation in chickens","volume":"25","author":"Lu","year":"2024","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.intimp.2025.114360_bb0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2147\/COPD.S144312","article-title":"Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition)","volume":"13","author":"Shen","year":"2018","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12011-017-1073-4","article-title":"Subchronic Arsenism disorders mRNA expression of cytokines and immunoglobulins in the intestinal tract of the cock","volume":"182","author":"Zhao","year":"2018","journal-title":"Biol. Trace Elem. Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0145","article-title":"A pathophysiological role of PDE3 in allergic airway inflammation","volume":"3","author":"Beute","year":"2018","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2025.114360_bb0150","series-title":"E. Diagnosis, Management, Phosphodiesterase 3 and 4 inhibition: facing a bright future in asthma control","volume":"87","author":"Beute","year":"2018"},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0155","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/10409238.2017.1304353","article-title":"The role of S-nitrosoglutathione reductase (GSNOR) in human disease and therapy","volume":"52","author":"Barnett","year":"2017","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.intimp.2025.114360_bb0160","series-title":"C101. Allergic Airway Inflammation and HYPERRESPONSIVENESS: Novel Mechanisms and Therapy, American Thoracic Society","first-page":"A5167","article-title":"A Novel therapeutic target in asthma: Translational evidence for inhibition of S-Nitrosoglutathione reductase","author":"Que","year":"2015"},{"key":"10.1016\/j.intimp.2025.114360_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pupt.2015.03.003","article-title":"Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment","volume":"32","author":"Hall","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/13543784.2019.1571582","article-title":"Experimental and investigational phosphodiesterase inhibitors in development for asthma","volume":"28","author":"Ntontsi","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.intimp.2025.114360_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2021.116597","article-title":"Environmentally relevant concentration of sulfamethoxazole-induced oxidative stress-cascaded damages in the intestine of grass carp and the therapeutic application of exogenous lycopene","volume":"274","author":"Wang","year":"2021","journal-title":"Environ. Pollut."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0180","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/all.13089","article-title":"Chemokine receptors in allergic diseases","volume":"72","author":"Castan","year":"2017","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2014present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.114360_bb0190","series-title":"Asthma: Definitions and Pathophysiology","first-page":"S2","author":"Mims","year":"2015"},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02632-1","article-title":"Regulatory T cells mediated immunomodulation during asthma: a therapeutic standpoint","volume":"18","author":"Khan","year":"2020","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0200","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2008.01.031","article-title":"Immunologic and inflammatory mechanisms that drive asthma progression to remodeling","volume":"121","author":"Broide","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.114360_bb0205","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1631\/jzus.B1700346","article-title":"Regulatory T cells and asthma","volume":"19","author":"Zhao","year":"2018","journal-title":"J. Zhejiang Univ.-Sci. B"},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0210","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1183\/09031936.05.00011205","article-title":"Regulatory T-lymphocytes in asthma","volume":"26","author":"Van Oosterhout","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0215","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1378\/chest.06-2434","article-title":"Regulatory T cells in allergy and asthma","volume":"132","author":"Larche","year":"2007","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.intimp.2025.114360_bb0220","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.coi.2006.09.007","article-title":"Immune dysregulation in asthma","volume":"18","author":"Umetsu","year":"2006","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2222.2005.02385.x","article-title":"Animal models of allergen-induced tolerance in asthma: are T-regulatory-1 cells (Tr-1) the solution for T-helper-2 cells (Th-2) in asthma?","volume":"36","author":"Tournoy","year":"2006","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0230","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaci.2005.07.015","article-title":"The role of T regulatory cells in asthma","volume":"116","author":"Seroogy","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.193.2.255","article-title":"Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2","volume":"193","author":"Hirai","year":"2001","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.114360_bb0240","first-page":"1942","article-title":"Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor","volume":"98","author":"Monneret","year":"2001","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0245","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/pr.110.003517","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress","volume":"63","author":"Woodward","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.intimp.2025.114360_bb0250","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prostaglandins.2017.08.006","article-title":"The therapeutic potential of CRTH2\/DP2 beyond allergy and asthma","volume":"133","author":"Jandl","year":"2017","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"10","key":"10.1016\/j.intimp.2025.114360_bb0255","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#","article-title":"CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease","volume":"30","author":"Cosmi","year":"2000","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.114360_bb0260","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/13543784.2016.1212838","article-title":"Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma","volume":"25","author":"Santus","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.intimp.2025.114360_bb0265","first-page":"165","article-title":"CRTH2 antagonists in asthma: current perspectives","volume":"9","author":"Singh","year":"2017","journal-title":"Clinical Pharmacol.: Adv. Appl."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0270","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/mol.115.101832","article-title":"Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy","volume":"89","author":"Sykes","year":"2016","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0275","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaci.2014.08.027","article-title":"D prostanoid receptor 2 (chemoattractant receptor\u2013homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells","volume":"135","author":"Stinson","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0280","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.201002-0295OC","article-title":"Mast cell phenotype, location, and activation in severe asthma: data from the severe asthma research program","volume":"183","author":"Balzar","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0285","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2249.2008.03871.x","article-title":"Interaction between prostaglandin D2 and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells","volume":"156","author":"Xue","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2025.114360_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104490","article-title":"New treatments for asthma: from the pathogenic role of prostaglandin d2 to the therapeutic effects of fevipiprant","volume":"155","author":"Pelaia","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0295","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2222.2011.03813.x","article-title":"A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma","volume":"42","author":"Barnes","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0300","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1183\/09031936.00092111","article-title":"Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459","volume":"41","author":"Singh","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.intimp.2025.114360_bb0305","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/all.12451","article-title":"Heightened response of eosinophilic asthmatic patients to the CRTH 2 antagonist OC 000459","volume":"69","author":"Pettipher","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.intimp.2025.114360_bb0310","series-title":"Druggable Prostanoid Pathway, Druggable Lipid Signaling Pathways","first-page":"29","author":"Mazaleuskaya","year":"2020"},{"issue":"8","key":"10.1016\/j.intimp.2025.114360_bb0315","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/cea.12357","article-title":"Setipiprant, a selective CRTH 2 antagonist, reduces allergen-induced airway responses in allergic asthmatics","volume":"44","author":"Diamant","year":"2014","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.intimp.2025.114360_bb0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pharmthera.2016.10.010","article-title":"Mast cell and eosinophil surface receptors as targets for anti-allergic therapy","volume":"170","author":"Gangwar","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0325","doi-asserted-by":"crossref","first-page":"P157","DOI":"10.2500\/aap.2017.38.4034","article-title":"A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma","volume":"38","author":"Miller","year":"2017","journal-title":"Allergy Asthma Proceedings"},{"issue":"11","key":"10.1016\/j.intimp.2025.114360_bb0330","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/jcph.947","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel CRTH2 antagonist BI 1021958 at single oral doses in healthy men and multiple oral doses in men and women with well-controlled asthma","volume":"57","author":"Fowler","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2025.114360_bb0335","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-Centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.intimp.2025.114360_bb0340","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2016.06.005","article-title":"The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma","volume":"39","author":"Erpenbeck","year":"2016","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0345","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/13543784.2018.1432592","article-title":"Fevipiprant in the treatment of asthma","volume":"27","author":"White","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.intimp.2025.114360_bb0350","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2147\/DDDT.S105142","article-title":"Two phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma","volume":"10","author":"Kuna","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2025.114360_bb0355","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/DDDT.S147389","article-title":"Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting \u03b22-agonists in patients with atopic asthma","volume":"12","author":"Bateman","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0360","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/13543784.2013.839658","article-title":"Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs","volume":"23","author":"Norman","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.12.037","article-title":"Safety and efficacy of ARRY-502, a potent, selective, Oral CRTh2 antagonist, in patients with mild to moderate Th2-driven asthma","volume":"133","author":"Wenzel","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Suppl 57","key":"10.1016\/j.intimp.2025.114360_bb0370","first-page":"P3401","article-title":"The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects","volume":"42","author":"Fitzgerald","year":"2013","journal-title":"Eur. Respiratory Soc."},{"key":"10.1016\/j.intimp.2025.114360_bb0375","series-title":"The In Vitro Profile of ADC3680, a Potent and Selective CRTh2 Antagonist for the Treatment of Inadequately Controlled Asthma","author":"Fitzgerald","year":"2013"},{"issue":"4","key":"10.1016\/j.intimp.2025.114360_bb0380","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0385","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ejps.2013.04.017","article-title":"Inhibition of antigen-induced airway inflammation and hyperresponsiveness in guinea pigs by a selective antagonist of \u201cchemoattractant receptor homologous molecule expressed on Th2 cells\u201d(CRTH2)","volume":"49","author":"Tasaki","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0390","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13543784.2019.1555237","article-title":"Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives","volume":"28","author":"Marone","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"10","key":"10.1016\/j.intimp.2025.114360_bb0395","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1177\/0091270011421912","article-title":"Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2","volume":"52","author":"Bain","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0400","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaci.2012.10.013","article-title":"Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients","volume":"131","author":"Busse","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0405","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1021\/ml1002234","article-title":"Discovery of AMG 853, a CRTH2 and DP dual antagonist","volume":"2","author":"Liu","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0410","first-page":"L767","article-title":"CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation","volume":"295","author":"Lukacs","year":"2008","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"8","key":"10.1016\/j.intimp.2025.114360_bb0415","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1365-2222.2008.03007.x","article-title":"CRTH2-dependent, STAT6-independent induction of cedar pollen dermatitis","volume":"38","author":"Oiwa","year":"2008","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0420","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1465-9921-8-16","article-title":"Antagonism of the prostaglandin D 2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation","volume":"8","author":"Uller","year":"2007","journal-title":"Respir. Res."},{"issue":"Suppl 56","key":"10.1016\/j.intimp.2025.114360_bb0425","first-page":"3084","article-title":"Efficacy and safety of BI 671800, an oral CRTH2 antagonist in controller na\u00efve patients with poorly-controlled asthma","volume":"40","author":"Sutherland","year":"2012","journal-title":"Eur. Respiratory Soc."},{"key":"10.1016\/j.intimp.2025.114360_bb0430","series-title":"Efficacy and Safety of BI 671800, an Oral CRTH2 Antagonist, as Add on Therapy in Poorly Controlled Asthma Patients Prescribed an Inhaled Corticosteroid","author":"Hall","year":"2012"},{"key":"10.1016\/j.intimp.2025.114360_bb0435","series-title":"Global Strategy for Asthma Management and Prevention: 2012 Update, Global Initiative for Asthma Vancouver, USA","author":"G.I.F.A. Program","year":"2017"},{"issue":"12","key":"10.1016\/j.intimp.2025.114360_bb0440","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-017-0777-2","article-title":"Targeting the PGD 2\/CRTH2\/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives","volume":"77","author":"Kupczyk","year":"2017","journal-title":"Drugs"},{"issue":"Suppl 59","key":"10.1016\/j.intimp.2025.114360_bb0445","first-page":"OA290","article-title":"LATE-BREAKING ABSTRACT: effect of QAW039, an oral prostaglandin D2 receptor (DP2\/CRTh2) antagonist, upon bronchial epithelial integrity in treatment-resistant asthma in a randomized, placebo controlled study","volume":"46","author":"Berair","year":"2015","journal-title":"Eur. Respiratory Soc."},{"issue":"Suppl 59","key":"10.1016\/j.intimp.2025.114360_bb0450","first-page":"PA2125","article-title":"QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: a proof-of-concept study","volume":"46","author":"Erpenbeck","year":"2015","journal-title":"Eur. Respiratory Soc."},{"issue":"Suppl. 58","key":"10.1016\/j.intimp.2025.114360_bb0455","article-title":"Late-breaking abstract: phase 2a randomized placebo-controlled trial of the oral prostaglandin D2 receptor (DP2\/CRTh2) antagonist QAW039 in eosinophilic asthma","volume":"44","author":"Gonem","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0460","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","article-title":"Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials","volume":"9","author":"Brightling","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0465","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1124\/jpet.111.180430","article-title":"Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation","volume":"338","author":"Bain","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2025.114360_bb0470","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1517\/13543776.2011.636738","article-title":"A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033","volume":"21","author":"Norman","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.intimp.2025.114360_bb0475","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.phrs.2016.06.014","article-title":"Pharmacological characterization of CRTh2 antagonist LAS191859: long receptor residence time translates into long-lasting in vivo efficacy","volume":"111","author":"Calbet","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.114360_bb0480","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/jm2013997","article-title":"Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2), From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis","volume":"55","author":"Pettipher","year":"2012","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0485","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1164\/rccm.200901-0158OC","article-title":"S-nitrosoglutathione reductase: an important regulator in human asthma","volume":"180","author":"Que","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.intimp.2025.114360_bb0490","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1164\/rccm.200905-0695OC","article-title":"Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma","volume":"181","author":"Dweik","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0495","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting T ype 2-high and T ype 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0500","first-page":"3173","article-title":"Biochimica et Biophysica Acta (BBA)-General Subjects","volume":"1830","author":"Broniowska","year":"2013","journal-title":"S-nitrosoglutathione"},{"issue":"5728","key":"10.1016\/j.intimp.2025.114360_bb0505","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1126\/science.1108228","article-title":"Protection from experimental asthma by an endogenous bronchodilator","volume":"308","author":"Que","year":"2005","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.intimp.2025.114360_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070351","article-title":"S-nitrosoglutathione reductase inhibition regulates allergen-induced lung inflammation and airway hyperreactivity","volume":"8","author":"Ferrini","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0515","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/iid3.220","article-title":"Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma","volume":"6","author":"Que","year":"2018","journal-title":"Immunity, inflammation Dis."},{"issue":"S1","key":"10.1016\/j.intimp.2025.114360_bb0520","first-page":"1","article-title":"S-Nitrosoglutathione reductase inhibition attenuates long term effects of neonatal Hyperoxia on airway Hyperreactivity","volume":"34","author":"Sopi","year":"2020","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0525","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yrtph.2011.12.012","article-title":"A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma","volume":"62","author":"Colagiovanni","year":"2012","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114360_bb0530","first-page":"1","article-title":"The precision interventions for severe and\/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations","author":"Ivanova","year":"2020","journal-title":"J. Biopharm. Stat."},{"issue":"12","key":"10.1016\/j.intimp.2025.114360_bb0535","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.4049\/jimmunol.163.12.6876","article-title":"Activation of eotaxin gene transcription by NF-\u03baB and STAT6 in human airway epithelial cells","volume":"163","author":"Matsukura","year":"1999","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114360_bb0540","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1084\/jem.20020009","article-title":"Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma","volume":"195","author":"Mattes","year":"2002","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.intimp.2025.114360_bb0545","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1021\/bi201785u","article-title":"Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase","volume":"51","author":"Green","year":"2012","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0550","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000368800","article-title":"Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease","volume":"165","author":"Page","year":"2014","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.intimp.2025.114360_bb0555","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/JEP.S242961","article-title":"New avenues for phosphodiesterase inhibitors in asthma","volume":"13","author":"Matera","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114360_bb0560","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fphar.2020.00609","article-title":"Respiratory cilia as a therapeutic target of phosphodiesterase inhibitors","volume":"11","author":"Joskova","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0565","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1165\/rcmb.2019-0274ED","article-title":"A new pathway to airway relaxation: targeting the \u201cother\u201d cyclase in asthma","volume":"62","author":"Lam","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.intimp.2025.114360_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101832","article-title":"An inherent dysfunction in soluble guanylyl cyclase is present in the airway of severe asthmatics and is associated with aberrant redox enzyme expression and compromised NO-cGMP signaling","volume":"39","author":"Ghosh","year":"2021","journal-title":"Redox Biol."},{"issue":"11","key":"10.1016\/j.intimp.2025.114360_bb0575","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.3390\/ijms21114008","article-title":"Pan-PDE inhibitor exerts anti-fibrotic effects in human lung fibroblasts via inhibition of TGF-\u03b2 signaling and activation of cAMP\/PKA signaling","volume":"21","author":"W\u00f3jcik-Pszczo\u0142a","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114360_bb0580","series-title":"Bronchodilator Therapy for Asthma, Allergy and Asthma: The Basics to Best Practices","first-page":"841","author":"Spahn","year":"2019"},{"key":"10.1016\/j.intimp.2025.114360_bb0585","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0590","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1046\/j.1365-2125.2002.01682.x","article-title":"Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE) 4 inhibitor V11294A in healthy volunteers","volume":"54","author":"Gale","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0595","doi-asserted-by":"crossref","DOI":"10.2174\/2589645801913010012","article-title":"The use of Milrinone conventional treatment for the Management of Life-Threatening Bronchial Asthma","volume":"13","author":"Sobhy","year":"2019","journal-title":"The Open Anesthesia J."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0600","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00000539-200107000-00046","article-title":"A comparison of the relaxant effects of olprinone and aminophylline on methacholine-induced bronchoconstriction in dogs","volume":"93","author":"Hirota","year":"2001","journal-title":"Anesth. Analg."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2025.114360_bb0605","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2009.07.005","article-title":"NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects","volume":"618","author":"Hori","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0610","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00003495-200059020-00004","article-title":"Phosphodiesterase 4 inhibitors and the treatment of asthma","volume":"59","author":"Giembycz","year":"2000","journal-title":"Drugs"},{"issue":"1\u20133","key":"10.1016\/j.intimp.2025.114360_bb0615","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2006.07.002","article-title":"Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma","volume":"547","author":"Deng","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0620","first-page":"1728","article-title":"Anti-inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B","volume":"19","author":"Zheng","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2025.114360_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1465-9921-11-26","article-title":"The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma","volume":"11","author":"Singh","year":"2010","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0630","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0022-3565(24)29524-0","article-title":"Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs","volume":"297","author":"Aoki","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2025.114360_bb0635","series-title":"Effects of Selective Inhibition of PDE4 by YM976 on Airway Reactivity and Cough in Ovalbumin-Sensitized guinea Pigs, Allergy and Respiration","first-page":"61","author":"Mokr\u00fd","year":"2016"},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0640","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000209608","article-title":"Pharmacology of a novel, orally active PDE4 inhibitor","volume":"83","author":"Dastidar","year":"2009","journal-title":"Pharmacology"},{"issue":"1\u20133","key":"10.1016\/j.intimp.2025.114360_bb0645","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejphar.2012.04.016","article-title":"Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin-induced asthma murine model","volume":"685","author":"Kwak","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2466-14-166","article-title":"The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma","volume":"14","author":"Leaker","year":"2014","journal-title":"BMC Pulm. Med."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0655","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2222.2000.00782.x","article-title":"Effect of aerosolized administration of KF19514, a phosphodiesterase 4 inhibitor, on bronchial hyperresponsiveness and airway inflammation induced by antigen inhalation in guinea-pigs","volume":"30","author":"Myou","year":"2000","journal-title":"Clin. Exp. Allergy"},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0660","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2332\/allergolint.08-OA-0053","article-title":"Effects of KF19514, a phosphodiesterase 4 and 1 inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma","volume":"58","author":"Kita","year":"2009","journal-title":"Allergol. Int."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0665","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1465-9921-6-128","article-title":"Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration","volume":"6","author":"Pullamsetti","year":"2005","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0670","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1183\/09031936.00002007","article-title":"Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3\/4 inhibition","volume":"31","author":"Dony","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.intimp.2025.114360_bb0675","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/13543784.10.7.1361","article-title":"Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease","volume":"10","author":"Giembycz","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0680","first-page":"L332","article-title":"Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers","volume":"287","author":"Barber","year":"2004","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"4","key":"10.1016\/j.intimp.2025.114360_bb0685","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0690","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1517\/13543784.16.1.109","article-title":"Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast","volume":"16","author":"Kroegel","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0695","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11897-017-0331-2","article-title":"Therapeutic targeting of PDEs and PI3K in heart failure with preserved ejection fraction (HFpEF)","volume":"14","author":"Sala","year":"2017","journal-title":"Curr. Heart Fail. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2025.114360_bb0700","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease","volume":"120","author":"Howell","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.intimp.2025.114360_bb0705","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.pupt.2015.08.006","article-title":"Roflumilast for asthma: efficacy findings in mechanism of action studies","volume":"35","author":"Bardin","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.114360_bb0710","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.pupt.2015.10.002","article-title":"Roflumilast for asthma: efficacy findings in non-placebo-controlled comparator and dosing studies","volume":"35","author":"Bateman","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.114360_bb0715","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.pupt.2015.11.003","article-title":"Roflumilast for asthma: safety findings from a pooled analysis of ten clinical studies","volume":"35","author":"Chervinsky","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.114360_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101814","article-title":"Efficacy and safety of a first-in-class inhaled PDE3\/4 inhibitor (ensifentrine) vs salbutamol in asthma","volume":"58","author":"Bjermer","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-019-1142-7","article-title":"Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD","volume":"20","author":"Singh","year":"2019","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0730","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jaci.2005.04.023","article-title":"Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions","volume":"116","author":"van Schalkwyk","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0735","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/00912700222011328","article-title":"The new phosphodiesterase 4 inhibitor Roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-\u03b1 ex vivo","volume":"42","author":"Timmer","year":"2002","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl. 38","key":"10.1016\/j.intimp.2025.114360_bb0740","first-page":"303S","article-title":"Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor is effective in the treatment of asthma","volume":"20","author":"Leichtl","year":"2002","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0745","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2015.11.035","article-title":"Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma","volume":"138","author":"Bateman","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0750","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/resp.13276","article-title":"Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: a systematic review and meta-analysis","volume":"23","author":"Luo","year":"2018","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0755","first-page":"85","article-title":"Roflumilast: first approved oral selective PDE4 inhibitor for the treatment of COPD","volume":"3","author":"Nizamudin","year":"2020","journal-title":"Int. J. Health Clin. Res."},{"key":"10.1016\/j.intimp.2025.114360_bb0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2016.06.011","article-title":"A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients","volume":"40","author":"Singh","year":"2016","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.114360_bb0765","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2018.06.007","article-title":"Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients","volume":"113","author":"Southworth","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2025.114360_bb0770","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2025.114360_bb0775","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1021\/jm030776l","article-title":"Synthesis and structure\u2212 activity relationships of cis-tetrahydrophthalazinone\/pyridazinone hybrids: a novel series of potent dual PDE3\/PDE4 inhibitory agents","volume":"46","author":"Van der Mey","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2025.114360_bb0780","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","article-title":"Phosphodiesterases as therapeutic targets for respiratory diseases","volume":"197","author":"Zuo","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2025.114360_bb0785","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","article-title":"Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials","volume":"1","author":"Franciosi","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.114360_bb0790","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.113.204644","article-title":"Effect of the mixed phosphodiesterase 3\/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone","volume":"346","author":"Calzetta","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2025.114360_bb0795","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/DDDT.S227432","article-title":"Hesperetin-5,7,3\u2019-O-Trimethylether dually inhibits phosphodiesterase 3\/4 and methacholine-induced airway Hyperresponsiveness in sensitized and challenged mice","volume":"14","author":"Shih","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2025.114360_bb0800","first-page":"1","article-title":"Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab","author":"E. Ridolo, F. Pucciarini, M.C. Nizi, E. Makri, P. Kihlgren, L. Panella, C. Incorvaia","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0805","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/joim.12382","article-title":"Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies","volume":"279","author":"Chung","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.intimp.2025.114360_bb0810","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2025.114360_bb0815","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/rccm.201807-1291OC","article-title":"A transcriptomic method to determine airway immune dysfunction in T2-high and T2-low asthma","volume":"199","author":"Peters","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.114360_bb0820","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/23808993.2020.1776106","article-title":"Phenotyping severe asthma: a rationale for biologic therapy","volume":"5","author":"Vatrella","year":"2020","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0825","first-page":"1394","article-title":"New targeted therapies for uncontrolled asthma, the journal of allergy and clinical immunology","volume":"7","author":"Corren","year":"2019","journal-title":"In Pract."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/cells13050384","article-title":"Eosinophilic asthma: pathophysiology and therapeutic horizons","volume":"13","author":"Hussain","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.114360_bb0835","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3389\/fimmu.2017.01835","article-title":"Effects of anti-IL-17 on inflammation, remodeling, and oxidative stress in an experimental model of asthma exacerbated by LPS","volume":"8","author":"Camargo","year":"2018","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.114360_bb0840","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1084\/jem.20061401","article-title":"Interleukin-17 is a negative regulator of established allergic asthma","volume":"203","author":"Schnyder-Candrian","year":"2006","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.intimp.2025.114360_bb0845","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1365-2222.2010.03544.x","article-title":"Induction of glucocorticoid receptor-\u03b2 expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines","volume":"40","author":"Vazquez-Tello","year":"2010","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-015-0307-2","article-title":"Th-17 regulatory cytokines inhibit corticosteroid induced airway structural cells apoptosis","volume":"17","author":"Halwani","year":"2016","journal-title":"Respir. Res."},{"issue":"suppl61","key":"10.1016\/j.intimp.2025.114360_bb0855","article-title":"The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients","volume":"50","author":"Khokhlovich","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.intimp.2025.114360_bb0860","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti\u2013IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2025.114360_bb0865","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40413-018-0208-1","article-title":"Potential new targets for drug development in severe asthma","volume":"11","author":"Zhu","year":"2018","journal-title":"World Allergy Organization J."},{"issue":"6","key":"10.1016\/j.intimp.2025.114360_bb0870","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1165\/rcmb.2015-0038OC","article-title":"IL-17RA signaling in airway inflammation and bronchial hyperreactivity in allergic asthma","volume":"53","author":"Willis","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114360_bb0875","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.201403-0505OC","article-title":"Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma","volume":"190","author":"Cheng","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114360_bb0880","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MCP.0000000000000615","article-title":"Anti-alarmin approaches entering clinical trials","volume":"26","author":"Gauvreau","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"9","key":"10.1016\/j.intimp.2025.114360_bb0885","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2025.114360_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109685","article-title":"Chimeric antigen receptor -T cell therapy: applications and challenges in treatment of allergy and asthma","volume":"123","author":"Esmaeilzadeh","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0895","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jocit.2016.08.001","article-title":"Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective","volume":"2","author":"Smith","year":"2016","journal-title":"J. Cellular Immunotherapy"},{"key":"10.1016\/j.intimp.2025.114360_bb0900","first-page":"23","article-title":"The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells, seminars in Cancer biology","author":"Ramachandran","year":"2017","journal-title":"Elsevier"},{"issue":"24","key":"10.1016\/j.intimp.2025.114360_bb0905","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2025.114360_bb0910","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20051166","article-title":"Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent","volume":"202","author":"Kearley","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2025.114360_bb0915","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","article-title":"Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of asthma","volume":"8","author":"Skuljec","year":"2017","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.114360_bb0920","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ni.1892","article-title":"The many paths to asthma: phenotype shaped by innate and adaptive immunity","volume":"11","author":"Kim","year":"2010","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114360_bb0925","first-page":"6293","article-title":"ML-7 attenuates airway inflammation and remodeling via inhibiting the secretion of Th2 cytokines in mice model of asthma","volume":"17","author":"Huang","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"14","key":"10.1016\/j.intimp.2025.114360_bb0930","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1128\/MCB.25.14.6259-6266.2005","article-title":"Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo","volume":"25","author":"Fazal","year":"2005","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114360_bb0935","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1086\/680357","article-title":"A nonmuscle myosin light chain kinase\u2013dependent gene signature in peripheral blood mononuclear cells is linked to human asthma severity and exacerbation status","volume":"5","author":"Zhou","year":"2015","journal-title":"Pulmonary Circulation"},{"issue":"10","key":"10.1016\/j.intimp.2025.114360_bb0940","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI24970","article-title":"Epithelial myosin light chain kinase\u2013dependent barrier dysfunction mediates T cell activation\u2013induced diarrhea in vivo","volume":"115","author":"Clayburgh","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2025.114360_bb0945","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1165\/rcmb.2013-0434OC","article-title":"Nonmuscle myosin light chain kinase regulates murine asthmatic inflammation","volume":"50","author":"Wang","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.intimp.2025.114360_bb0950","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fphar.2017.00292","article-title":"Myosin light chain kinase: a potential target for treatment of inflammatory diseases","volume":"8","author":"Xiong","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114360_bb0955","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00056-2019","article-title":"Efficacy of azithromycin in severe asthma from the AMAZES randomised trial","volume":"5","author":"Gibson","year":"2019","journal-title":"ERJ Open Res."},{"issue":"10095","key":"10.1016\/j.intimp.2025.114360_bb0960","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:05:26Z","timestamp":1757912726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925003509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":192,"alternative-id":["S1567576925003509"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114360","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe asthma beyond bronchodilators: Emerging therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114360"}}